Land: Armenien
Sprog: engelsk
Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
ceftriaxone (ceftriaxone sodium)
Hankook Korus Pharm Co.
J01DD04
ceftriaxone (ceftriaxone sodium)
1000mg
powder for solution for i/m injection
(1) glass vial and 3,5ml solvent in ampoule
Prescription
Registered
2019-07-18
[ COMPOSITION ] Each vial contains: Ceftriaxone sodium ----------------------------------------------------------------------- 1.0g(Potency) [ INDICATIONS ] Ceftriaxone-Asteria Inj. 1g is indicated for the treatment of the following infections in adults and children including term neonates (from birth): Bacterial Meningitis Community acquired pneumonia Hospital acquired pneumonia Acute otitis media Intra-abdominal infections Complicated urinary tract infections (including pyelonephritis) Infections of bones and joints Complicated skin and soft tissue infections Gonorrhoea Syphilis Bacterial endocarditis Ceftriaxone-Asteria Inj. 1g may be used: For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age For Pre-operative prophylaxis of surgical site infections In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above Ceftriaxone-Asteria Inj. 1g should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum. Consideration should be given to official guidelines on the appropriate use of antibacterial agents. [ ADMINISTRATION ] The dose depends on the severity, susceptibility, site and type of infection and on the age and hepato-renal function of the patient. The doses recommended in the tables below are the generally recommended doses in these indications. In particularly severe cases, doses at the higher end of the recommended range should be considered. _Adults and children over 12 years of age (≥ 50kg)_ Ceftriaxone Dosage* Treatment frequency** Indications 1 - 2 g Once daily Community acquired pneumonia Acute exacerbations of chronic obstructive pulmonary diseas Læs hele dokumentet
SUMMARY OF PRODUCT CHARACTERISTIC (SPC) OF CEFTRIAXONE-ASTERIA INJ. 1G HANKOOK KORUS PHARM. CO., LTD. 11, GEODUDANJI 1-GIL, DONGNAE-MYEON, CHUNCHEON-SI, GANGWON-DO, KOREA 1. NAME OF THE MEDICINAL PRODUCT Ceftriaxone-Asteria Inj. 1g 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient No. Chemical Name Quantity/vial Use 1 Ceftriaxone sodium 1g (potency) Active ingredient ATC Code: J01DD04 Excipient(s) None 3. PHARMACEUTICAL FORM Power for Solution for I/M injection 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Ceftriaxone-Asteria Inj. 1g is indicated for the treatment of the following infections in adults and children including term neonates (from birth): Bacterial Meningitis Community acquired pneumonia Hospital acquired pneumonia Acute otitis media Intra-abdominal infections Complicated urinary tract infections (including pyelonephritis) Infections of bones and joints Complicated skin and soft tissue infections Gonorrhoea Syphilis Bacterial endocarditis Ceftriaxone-Asteria Inj. 1g may be used: For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age For Pre-operative prophylaxis of surgical site infections In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above Ceftriaxone-Asteria Inj. 1g should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum (see section 4.4). Consideration should be given to official guidelines on the appropriate use of antibacterial agents. 4.2 Posology and method of administration Posology The dose depends on the severity, susceptibility, site and type of infection and on the age and hepato-renal function of the pa Læs hele dokumentet